SI
AEGR

Stephens Inc’s Aegerion Pharmaceuticals AEGR Stock Holding History

Stephens Inc’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-6,000
Closed -$426K – 943
2013
Q4 		$426K Hold
6,000
– – 0.02% 556
2013
Q3 		$515K Hold
6,000
– – 0.03% 460
2013
Q2 		$380K Buy
+6,000
New +$319K 0.02% 488

Other funds holding AEGR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Stephens Inc's AEGR Position: Q1 2014 in Review

Stephens Inc sold out of Aegerion Pharmaceuticals (AEGR) in Q1 2014, closing a stake of 6,000 shares — an estimated $426K sold.

Stephens Inc first reported a position in AEGR in Q2 2013 and held it in 3 quarters. The position peaked at $515K in Q3 2013. 131 funds tracked by Wall St. Rank hold AEGR as of Q1 2014.

  • Stephens Inc reported no remaining Aegerion Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Stephens Inc sold 6,000 Aegerion Pharmaceuticals shares in Q1 2014, an estimated $426K.
  • Stephens Inc first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • Stephens Inc's Aegerion Pharmaceuticals position peaked at $515K in Q3 2013.
  • 131 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q1 2014.

Based on Stephens Inc's 13F filing for Q1 2014, filed 13 May 2014.